<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036512</url>
  </required_header>
  <id_info>
    <org_study_id>GBT021601-011</org_study_id>
    <nct_id>NCT05036512</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, PK, and Food Effect of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Healthy Participants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics&#xD;
      (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled, single and multiple ascending dose&#xD;
      study in healthy participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, as assessed by frequency and severity of adverse events (AEs)</measure>
    <time_frame>119 days from screening Part A, 134 days from screening Part B</time_frame>
    <description>AEs will be coded to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as assessed by changes in Heart Rate.</measure>
    <time_frame>119 days from screening Part A, 134 days from screening Part B</time_frame>
    <description>Number of participants with changes in heart rate (bpm) as compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as assessed by changes in eGFR</measure>
    <time_frame>119 days from screening Part A, 134 days from screening Part B</time_frame>
    <description>Number of participants with changes in eGFR from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as assessed by changes in alanine aminotransferase (ALT)</measure>
    <time_frame>119 days from screening Part A, 134 days from screening Part B</time_frame>
    <description>Number of participants with changes in alanine aminotransferase (ALT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as assessed by changes in Blood pressure</measure>
    <time_frame>119 days from screening Part A, 134 days from screening Part B</time_frame>
    <description>Number of participants with changes in systolic (mmHg) and diastolic (mmHg) blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>119 days from screening Part A</time_frame>
    <description>Time of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>134 days from screening Part B</time_frame>
    <description>Cmax on D1-D15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine whole blood concentration of GBT021601</measure>
    <time_frame>119 days from screening Part A</time_frame>
    <description>Hemoximetry will be used to assess oxygen saturation in whole blood by generating oxygen equilibrium curves (OECs) which relate the extent of Hb-O2 saturation to the partial pressure of O2 (pO2) and measure the binding affinity of O2 to Hb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine plasma concentration of GBT021601.</measure>
    <time_frame>134 days from screening Part B</time_frame>
    <description>With dosing data from each cohort determine the steady-state maximum plasma/whole blood concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, as assessed by changes in QTcF</measure>
    <time_frame>119 days from screening Part A, 134 days from screening Part B</time_frame>
    <description>Number of participants with changes in the QTcF interval from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as a tablet or capsule with dose based off of preceding cohort's data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT021601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT021601</intervention_name>
    <description>Administered orally with water as a single dose in the morning.</description>
    <arm_group_label>GBT021601</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females ≥ 18 to ≤ 55 years of age&#xD;
&#xD;
          -  Body mass index ≥ 18.0 to ≤ 30.0 kg/m2&#xD;
&#xD;
          -  Body weight ≥ 50 kg at screening and Day -1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Positive pregnancy test or currently breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleanor Lisbon, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>GBT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Guider, MS, MPH, MBA</last_name>
    <phone>630-364-3275</phone>
    <email>jguider@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleanor Lisbon, MD, MPH</last_name>
    <phone>650-781-1765</phone>
    <email>elisbon@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICON Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Key, MD</last_name>
      <phone>210-283-4120</phone>
      <email>Cassandra.Key@iconplc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Redfern, MD</last_name>
      <phone>+61 (0) 433 078 719</phone>
      <email>aredfern@linear.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

